IMDX Q2 Loss Widens to $10.9M Amid Revenue Dip

TL;DR

**IMDX is bleeding cash with widening losses and falling revenue; steer clear until they show a path to profitability.**

AI Summary

Insight Molecular Diagnostics Inc. (IMDX) reported a net loss of $10.9 million for the three months ended June 30, 2025, a significant increase from the $7.8 million net loss in the prior-year period. Revenue for the quarter was $1.2 million, down from $1.5 million in the same period last year, representing a 20% decrease. The company's strategic outlook includes the continued development of its DetermaIO and DetermaCNI products, with a focus on the European market, as evidenced by the mention of 'srt:EuropeMember'. Key business changes include the acquisition of Chronix Biomedical in 2024, which is expected to contribute to future revenue streams, and a securities purchase agreement with Broadwood Partners, L.P. on February 10, 2025, for common stock. Risks highlighted include customer concentration, with 'Company A' accounting for a significant portion of sales, and the ongoing need for additional capital to fund operations, as indicated by the $10.9 million net loss. The company also noted a gain on the sale of other assets of $0.1 million for the six months ended June 30, 2025.

Why It Matters

IMDX's widening net loss and declining revenue signal significant challenges for investors, raising concerns about profitability and cash burn. The company's reliance on 'Company A' for a substantial portion of its sales revenue introduces customer concentration risk, making it vulnerable to changes in that relationship. For employees, continued losses could lead to restructuring or workforce reductions, while customers might face uncertainty regarding product development and support. In the competitive molecular diagnostics market, IMDX's financial performance could hinder its ability to innovate and compete effectively against larger, more established players, potentially impacting its market share and long-term viability.

Risk Assessment

Risk Level: high — The risk level is high due to a net loss of $10.9 million for the three months ended June 30, 2025, an increase from $7.8 million in the prior-year period, and a 20% decrease in revenue to $1.2 million. This indicates a deteriorating financial position and significant cash burn, with no clear path to profitability in the near term.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to IMDX. The company's widening losses and declining revenue suggest fundamental operational challenges that need to be addressed before it becomes an attractive investment.

Financial Highlights

revenue

$1.2M

net Income

-$10.9M

revenue Growth

-20.0%

Revenue Breakdown

Key Numbers

• $10.9M — Net Loss (for the three months ended June 30, 2025, up from $7.8M in prior year)
• $1.2M — Revenue (for the three months ended June 30, 2025, down 20% from $1.5M)
• 20% — Revenue Decrease (year-over-year decrease for the three months ended June 30, 2025)
• $0.1M — Gain on Sale of Other Assets (for the six months ended June 30, 2025)
• 2025-06-30 — Conformed Period of Report (end date of the reporting period)
• 2025-08-11 — Filed As Of Date (date the 10-Q was filed)

Key Players & Entities

• Insight Molecular Diagnostics Inc. (company) — filer of the 10-Q
• Broadwood Partners, L.P. (company) — investor in a securities purchase agreement on February 10, 2025
• Chronix Biomedical (company) — acquired by IMDX in 2024
• Company A (company) — significant customer concentration risk for IMDX
• Bio-Rad Laboratories Inc. (company) — party to a securities purchase agreement on April 15, 2024
• Insight Genetics Inc. (company) — entity related to Level 3 fair value inputs
• SEC (regulator) — recipient of the 10-Q filing
• Europe (location) — strategic market focus for IMDX

FAQ

Risk Factors

• Need for Additional Capital [high — financial]: The company reported a net loss of $10.9 million for the three months ended June 30, 2025, indicating a significant ongoing need for capital to fund operations and future development. This is further underscored by the net loss increasing from $7.8 million in the prior-year period.
• Customer Concentration [medium — operational]: A significant portion of the company's sales are attributable to a single customer, 'Company A'. This concentration presents a risk, as the loss of this customer could materially impact revenue and financial performance.
• Product Development and Market Adoption [medium — market]: The company's strategic outlook relies on the continued development of its DetermaIO and DetermaCNI products. Success is dependent on market adoption, particularly in the European market ('srt:EuropeMember'), and competitive pressures within the molecular diagnostics space.

Industry Context

The molecular diagnostics industry is characterized by rapid technological advancements and a growing demand for personalized medicine. Companies in this sector focus on developing innovative diagnostic tests for various diseases, including cancer. Key trends include the integration of artificial intelligence for data analysis and the expansion of liquid biopsy technologies. The competitive landscape is dynamic, with both established players and emerging companies vying for market share.

Regulatory Implications

Companies in the molecular diagnostics sector are subject to stringent regulatory oversight from bodies like the FDA. Compliance with quality standards, data privacy regulations (e.g., HIPAA), and approval processes for new diagnostic tests are critical. Changes in healthcare policy and reimbursement rates can also significantly impact market access and revenue.

What Investors Should Do

1. Monitor revenue trends closely, especially the impact of the Chronix acquisition and European market expansion.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the risk associated with customer concentration, particularly 'Company A'.
4. Track the progress and market penetration of DetermaIO and DetermaCNI products.

Key Dates

• 2025-06-30: End of Reporting Period — This is the period-end date for the 10-Q filing, reflecting the company's financial and operational status.
• 2025-08-11: 10-Q Filing Date — Indicates when the company officially submitted its quarterly report to the SEC.
• 2025-02-10: Securities Purchase Agreement with Broadwood Partners, L.P. — This agreement for common stock issuance is a key event related to the company's financing activities.
• 2024-01-01: Chronix Acquisition — The acquisition of Chronix Biomedical in 2024 is a significant strategic move expected to impact future revenue streams.
• 2024-04-01: Customer Concentration Risk Identified — The period for which customer concentration risk, specifically with 'Company A', was noted, highlighting a key operational risk.
• 2023-01-01: DetermaIO Product Mentioned — Indicates the period during which the DetermaIO product was a focus, part of the company's ongoing product development efforts.

Glossary

srt:EuropeMember

A tag indicating a focus or presence within the European market. (Highlights the company's strategic focus on expanding into Europe for its products like DetermaIO and DetermaCNI.)

imdx:ChronixMergerMember

Refers to the merger or acquisition involving Chronix. (This event is a key business change that is expected to contribute to future revenue streams for Insight Molecular Diagnostics.)

us-gaap:SalesRevenueNetMember

The total revenue generated from the sale of goods or services, net of returns, allowances, and discounts. (This is the primary measure of the company's top-line performance, which showed a 20% decrease year-over-year.)

us-gaap:CustomerConcentrationRiskMember

A risk associated with having a significant portion of revenue derived from a small number of customers. (Identified as a risk, with 'Company A' being a major contributor to sales, posing a threat if this customer is lost.)

us-gaap:CommonStockMember

Represents ownership in a corporation, typically with voting rights. (Relevant to financing activities, such as the securities purchase agreement with Broadwood Partners, L.P.)

http://fasb.org/us-gaap/2024#GainLossOnSaleOfOtherAssets

Represents the profit or loss realized from the disposal of assets that are not part of the company's primary operations. (A $0.1 million gain was reported for the six months ended June 30, 2025, contributing to the overall financial results.)

Year-Over-Year Comparison

Insight Molecular Diagnostics Inc. reported a significant increase in net loss to $10.9 million for the three months ended June 30, 2025, up from $7.8 million in the prior year. Revenue also saw a decline of 20%, falling to $1.2 million from $1.5 million in the same period last year. While the company is pursuing strategic growth through acquisitions like Chronix Biomedical and focusing on European markets, the increased losses and decreased revenue suggest ongoing financial pressures and challenges in market adoption.

Filing Documents

• imdx-20250630.htm (10-Q) — 3579KB
• imdx-ex31_1.htm (EX-31.1) — 14KB
• imdx-ex31_2.htm (EX-31.2) — 14KB
• imdx-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-25-106552.txt ( ) — 14310KB
• imdx-20250630.xsd (EX-101.SCH) — 1656KB
• imdx-20250630_htm.xml (XML) — 3160KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 CONDENSED CONSOLIDATED BALANCE SHEETS 3 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 4 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 5 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS' EQUITY 6 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 8 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 43

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 55

Controls and Procedures

Item 4. Controls and Procedures 55

- OTHER INFORMATION

PART II - OTHER INFORMATION 56

Legal Proceedings

Item 1. Legal Proceedings 56

Risk Factors

Item 1A. Risk Factors 56

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 57

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 58

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 58

Other Information

Item 5. Other Information 58

Exhibits

Item 6. Exhibits 59

SIGNATURES

SIGNATURES 60 1 Table of Contents CAUTIONARY NO TE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this Quarterly Report on Form 10-Q (this "Report") are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Insight Molecular Diagnostics Inc., or iMDx (f/k/a Oncocyte Corporation), along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Any statements that are not historical fact (including, but not limited to statements that contain words such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would" or similar expressions or the negative of such terms) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of iMDx, particularly those mentioned in this Report under Risk Factors and those Risk Factors in Part I, Item 1A. of our most recent Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission ("SEC"). Except as required by law, iMDx undertakes no obligation to update any forward-looking statements to reflect events or circumstances afte

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. INSIGHT MOLECULAR DIAGNOSTICS INC. CONDENSED CONS OLIDATED BALANCE SHEETS (In thousands) June 30, 2025 December 31, 2024 (Unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 24,287 $ 8,636 Accounts receivable, net of allowance for credit losses of $ 5 and $ 16 , respectively 512 1,613 Inventories 693 410 Deferred financing costs — 279 Prepaid expenses and other current assets 1,350 821 Total current assets 26,842 11,759 NONCURRENT ASSETS Right-of-use and financing lease assets, net 2,524 2,757 Machinery and equipment, net, and construction in progress 4,149 3,567 Intangible assets, net 14,600 14,607 Restricted cash 1,700 1,700 Other noncurrent assets 702 691 TOTAL ASSETS $ 50,517 $ 35,081 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) CURRENT LIABILITIES Accounts payable $ 1,277 $ 2,279 Accrued compensation 1,459 1,939 Accrued royalties 1,116 1,116 Accrued expenses and other current liabilities 571 418 Right-of-use and financing lease liabilities, current 1,540 1,295 Contingent consideration liabilities, current 689 228 Total current liabilities 6,652 7,275 NONCURRENT LIABILITIES Right-of-use and financing lease liabilities, noncurrent 1,834 2,369 Contingent consideration liabilities, noncurrent 40,933 37,711 TOTAL LIABILITIES 49,419 47,355 Commitments and contingencies (Note 6) SHAREHOLDERS' EQUITY (DEFICIT) Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding — — Common stock, no par value, 230,000 shares authorized; 28,617 and 17,453 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 367,965 338,244 Accumulated other comprehensive income 85 21 Accumulated deficit ( 366,952 ) ( 350,539 ) Total shareholders' equity (deficit) 1,098 ( 12,274 ) TOTAL LIABIL

View Full Filing

View this 10-Q filing on SEC EDGAR